Clinical trials · North Carolina
Ulcerative Colitis clinical trials in North Carolina
We’re tracking 26 recruiting ulcerative colitis studies with a site in North Carolina — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Chapel Hill, North CarolinaAges 18 years+ - NCT07415044RecruitingPhase 2
Study of LY4268989 for moderate to severe ulcerative colitis
This study tests an investigational medication called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It's for people who have tried other treatments without success. The goal is to see if the drug can reduce inflammation and improve symptoms.
Greenville, North CarolinaAges 18–80 - NCT07296315RecruitingPhase 2
Testing a new treatment for mild-to-moderate ulcerative colitis
This study tests an investigational drug for people with active mild-to-moderate ulcerative colitis. It aims to see if the drug can improve symptoms without needing advanced treatments like biologics.
Fayetteville, North CarolinaAges 16 years+ - NCT07196748RecruitingPhase 3
Icotrokinra for adults and teens with moderate to severe ulcerative colitis
This trial tests a new oral medication, icotrokinra, for people with moderately to severely active ulcerative colitis. It may be an option if you have not responded well enough to standard treatments or newer advanced therapies.
Charlotte, North CarolinaAges 12 years+ - NCT07185009RecruitingPhase 3
Testing duvakitug for long-term ulcerative colitis control
This study tests the long-term safety and effectiveness of an experimental drug called duvakitug in people with moderate to severe ulcerative colitis. It is for those who have already responded well to treatment in a previous study and need ongoing care.
Fayetteville, North CarolinaAges 16–80 - NCT07184996RecruitingPhase 3
Study of duvakitug for moderate to severe ulcerative colitis
This study tests a new drug called duvakitug for people with moderate to severe ulcerative colitis that hasn't been helped enough by standard treatments. The goal is to see if this medicine can reduce inflammation and improve symptoms.
Chapel Hill, North CarolinaAges 16–80 - NCT07012395RecruitingPhase 2
Long-acting antibodies for moderate to severe ulcerative colitis
This study tests new long-acting antibodies, given alone or in combination, for people with moderate to severe ulcerative colitis. The goal is to see if these treatments can help reduce inflammation and improve symptoms.
Chapel Hill, North CarolinaAges 18–75 - NCT06636656RecruitingPhase 2
Testing a new drug for ulcerative colitis after other treatments failed
This study tests a new medication called BI 3032950 for people with ulcerative colitis who have already tried other advanced treatments (biologics or targeted therapies) that didn't work well enough or caused problems. The goal is to see if the new drug is safe and helps control inflammation in the colon.
Charlotte, North CarolinaAges 18–80 - NCT06619990RecruitingPhase 1/Phase 2
Study of XmAb942 for active ulcerative colitis
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
Raleigh, North CarolinaAges 18–75 - NCT04314375RecruitingPhase 4
Budesonide tablets for children with mild to moderate ulcerative colitis
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
Greenville, North CarolinaAges 5–17 - NCT06398626Recruiting
Observational study of etrasimod for ulcerative colitis
This study watches how well etrasimod works for adults with moderate to severe ulcerative colitis (UC). You must already be prescribed etrasimod by your doctor, and the study collects information through a web-based tool.
Chapel Hill, North CarolinaAges 18–64 - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Chapel Hill, North CarolinaAges 2–17 - NCT06979336RecruitingPhase 2
New drug for moderate to severe UC
This study tests an experimental drug called RO7837195 for people with moderate to severe ulcerative colitis (UC) who haven't gotten enough help from other treatments. It aims to see if this new drug can reduce inflammation and improve symptoms.
Monroe, North CarolinaAges 18 years+ - NCT06095128RecruitingPhase 4
Combination therapy for ulcerative colitis
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Asheville, North CarolinaAges 18–65 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Asheville, North CarolinaAges 18–75 - NCT05953402Recruiting
Testing ozanimod use in pregnant people with ulcerative colitis
This trial studies how ozanimod affects pregnant people with ulcerative colitis and their babies. It may help doctors understand safety and outcomes when this medicine is used during pregnancy and after birth.
Wilmington, North CarolinaAges Any age - NCT06937086RecruitingPhase 3
Mirikizumab plus tirzepatide for UC with obesity
This study tests whether adding mirikizumab to the weight-loss drug tirzepatide helps people with moderate-to-severe ulcerative colitis who also have obesity or overweight. It aims to see if the combination reduces bowel inflammation and helps with weight management.
Fayetteville, North CarolinaAges 18–70 - NCT06581328RecruitingPhase 4
Study of vedolizumab for ulcerative colitis or Crohn's disease
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
Charlotte, North CarolinaAges 18–80 - NCT06424769Enrolling by invitation
Managing Inflammatory Bowel Disease with Text Message Surveys
This study aims to improve care and reduce health gaps for people with inflammatory bowel disease using text-message surveys to track symptoms and guide better disease management.
Chapel Hill, North CarolinaAges 13 years+ - NCT07237516Recruiting
Study of Zymfentra for people with Crohn's or colitis
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
Winston-Salem, North CarolinaAges 18 years+ - NCT07654751RecruitingPhase 4
Study of Tremfya in breast milk of breastfeeding women
This study measures how much Tremfya (guselkumab) gets into breast milk for women who are already taking it for conditions like psoriasis or arthritis and choose to breastfeed. It helps understand if the drug passes to the baby.
Chapel Hill, North CarolinaAges 18 years+ - NCT07198113Recruiting
Comparing newer treatments for pediatric inflammatory bowel disease
This study is for children and teens with inflammatory bowel disease (Crohn's, colitis, or indeterminate) whose previous anti-TNF medicine stopped working. It compares several newer treatments to see which works best.
Durham, North CarolinaAges 1–18 - NCT07113522RecruitingPhase 2
Study of new therapies for Crohn's and colitis
This trial tests new therapies for people with moderate to severe Crohn's disease or ulcerative colitis. It may help if your standard treatments aren't working well enough.
High Point, North CarolinaAges 18–80 - NCT06750731Recruiting
IV vs. shot vedolizumab for IBD with remote check-ins
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Chapel Hill, North CarolinaAges 18 years+
Ulcerative Colitis trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting ulcerative colitis studies listed above.
- University of North Carolina · 4 studies
- Atrium Health · 2 studies
- Carolina Digestive Diseases and Endoscopy Center · 2 studies
- Cross Creek Medical Clinic - Site Number: 8400057 · 2 studies
- Digestive Health Partners · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- 040
- Atrium Health Center for Gastroenterology and Surgery
What taking part in a ulcerative colitis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Ulcerative Colitis trials in other states
Common questions
- Are there ulcerative colitis clinical trials in North Carolina?
- Yes. We're currently tracking 26 recruiting ulcerative colitis studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a ulcerative colitis study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New ulcerative colitis studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.